laitimes

[China's first original target gene therapy for hemophilia B was born in Chengdu Bio-City] # Xiaobu Broadcast # On February 9, the reporter noticed that the official website of the government service platform of the Ministry of Science and Technology of the People's Republic of China was updated

author:Released in Chengdu

【China's first original target gene therapy for hemophilia B was born in Chengdu Bio-City】#Xiaobu Broadcast #On February 9, the reporter noticed that the official website of the government service platform of the Ministry of Science and Technology of the People's Republic of China updated the administrative licensing of Chinese genetic resources in 2022, and the second batch of approval results were released, which "Clinical study evaluating the safety and efficacy of ZS801 adeno-associated virus vector expression of human coagulation factor IX gene therapy technology in patients with hemophilia B" Clinical studies of AAV (adeno-associated virus) gene therapy were reviewed by the Office of Chinese Genetic Resources Management. It is reported that the project is jointly initiated by Sichuan Zhishan Weixin Biotechnology Co., Ltd., an enterprise located in Chengdu Tianfu International Biological City, and will carry out clinical research in the Hematology Hospital of the Chinese Academy of Medical Sciences. Jinguan News

[China's first original target gene therapy for hemophilia B was born in Chengdu Bio-City] # Xiaobu Broadcast # On February 9, the reporter noticed that the official website of the government service platform of the Ministry of Science and Technology of the People's Republic of China was updated

Read on